Sendai Virus iPSC Generation for Safe Conditioned Media
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) face challenges due to the use of animal-derived materials, insertional mutagenesis risks, and inefficiencies in DNA-based approaches, necessitating a safer and more reproducible non-DNA based method for clinical applications.
Innovation Solution
The use of Sendai virus vectors incorporating nuclear reprogramming factors like KLF, OCT, and SOX genes, delivered in a specific order, to induce dedifferentiation of somatic cells into pluripotent stem cells, avoiding integration into the host genome and enabling stable expansion of mesenchymal progenitor cells for conditioned media production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based methods are used to generate iPSCs, then reprogramming efficiency can be achieved, but insertional mutagenesis risks and safety issues arise
Solution Approach 1:
The patent extracts the essential reprogramming function from DNA-based methods by using only the mRNA transcripts of reprogramming factors (Oct4, Sox2, Klf4, c-Myc) without the DNA integration step. This removes the harmful insertional mutagenesis while preserving the cell reprogramming capability, directly resolving the safety contradiction.
Solution Approach 2:
The patent uses mRNA as an intermediary carrier to deliver reprogramming factors into somatic cells. Instead of directly integrating DNA into the genome, the mRNA temporarily expresses the reprogramming proteins in the cytoplasm, achieving reprogramming without genomic integration and thus eliminating insertional mutagenesis risks.
2Reliability
If animal-derived materials are used in iPSC generation, then reprogramming can be achieved, but contamination risks and immunogenicity issues arise
Solution Approach 1:
The patent changes the cultural parameters from animal-derived supplements to fully defined human-derived components. The culture medium uses human serum albumin and other human-based supplements instead of fetal bovine serum, eliminating xenogeneic contamination risks while maintaining cell growth and reprogramming efficiency.
3Reliability
If traditional MSC culture methods are used, then cell production is straightforward, but regenerative capacity and immunomodulatory properties are limited
Solution Approach 1:
The patent performs preliminary reprogramming of MSCs into induced pluripotent stem cells before differentiation. This preliminary action endows the cells with enhanced regenerative capacity and immunomodulatory properties by activating stemness genes and epigenetic reprogramming, which then translate to superior therapeutic efficacy after differentiation back to MSC-like cells.
Solution Approach 2:
The patent changes the epigenetic parameters of MSCs through reprogramming and differentiation cycles. By inducing pluripotency and then redifferentiating, the cells acquire modified epigenetic states that enhance their regenerative capacity and immunomodulatory function, resolving the efficacy limitation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the generation of stable, expandable pluripotent stem cells that can produce conditioned media with enhanced regenerative and immunomodulatory properties, addressing the limitations of existing iPSC generation methods.
Implementation Method 1
The use of Sendai virus vectors incorporating nuclear reprogramming factors like KLF, OCT, and SOX genes, delivered in a specific order, to induce dedifferentiation of somatic cells into pluripotent stem cells
Data Source
AI summary
Disclosed are means, methods and compositions of matter useful for generation of conditioned media from mesenchymal stem cells (MSC). In one embodiment MSC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the MSC lineage. The differentiated MSC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment MSC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.